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Detection of decreasing amount of methylated 
NTRK3 in serial dilutions of methylated and 
unmethylated DNA standards containing 100%, 
20%, 4%, 0.8%, 0.16%, 0.032%, 0.006% and 0% of 
methylated DNA (20 ng DNA/sample), as shown by 
ddPCR analysis. Each sample was partitioned into 
an average of 15,000 droplets per well and 
replicated in 4 wells. The droplet counts (positive 
and negative) from all 4 replicates were combined 
for the final analysis. An event with fluorescence 
amplitude value >4,500 was considered a 
methylation-positive event (red line). The number of 
methylation-positive events decreased as the 
methylated DNA was progressively diluted with 
unmethylated DNA. Using ddPCR, it was feasible to 
detect and absolutely quantify as low as 0.032% of 
methylated NTRK3 
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The addition of methyl groups to DNA is a process that plays an important role in development and 
in certain diseases, through altering gene expression in cells. Abnormal DNA methylation patterns - 
either higher or lower levels compared with normal tissue - are associated with many human 
malignancies, including colorectal cancer. Interestingly, these alterations have been detected not 
only in colon cancer and colon polyps, the precursors to colorectal cancer, but also in the normal 
colon tissue in individuals with concurrent colorectal cancer, who are at high risk of colon polyps and 
metachronous (not synchronous) colorectal cancer. Thus, there is potential for methylated genes to 
be used as biomarkers for early detection of colorectal cancer. There is a problem, however: the 
aberrations are present at very low levels, and cannot be easily detected using current polymerase 
chain reaction (PCR) technologies. Dr. Ming Yu in the laboratory of Dr. William Grady in Fred 
Hutch's Clinical Research Division accepted this challenge, and set out to develop a more precise 
and sensitive method for detecting methylated DNA. In the September issue of Epigenetics, Drs. Yu, 
Grady, and colleagues describe their efforts to develop this method and their resulting conclusions. 
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The investigators based their innovation on a conventional methylation-specific PCR method called 
MethyLight, but added the benefits of droplet digital PCR (ddPCR) - a new technology that enables 
precise detection of nucleic acid targets in clinical samples. Using colon cancer tissue samples and 
colon mucosa biopsy samples, the technique was tested for detecting infrequently methylated alleles 
- an application of ddPCR that had not been previously published. "In our study, we developed a 
ddPCR version of MethyLight assays and demonstrated that the resulting MethyLight ddPCR offered 
improvements in sensitivity with a much lower limit of detection, improved absolute quantification of 
methylated alleles, as well as increased precision in detecting infrequently methylated targets," Dr. 
Yu said. 
The investigators used the BioRad QX200 ddPCR system, which partitions each 20-µL PCR 
reaction into an average of 15,000 nanoliter droplets through water-oil emulsion. Essentially, this 
enables 15,000 simultaneous independent PCR reactions, with each droplet PCR-cycled to endpoint 
and read with a two-color fluorescence reader. Thus, it is possible to determine how many droplets 
are positive. Compared with conventional MethyLight PCR, the respective limits of quantification and 
detection were 25 and 20 times lower with MethyLight ddPCR, as determined through comparative 
analysis of methylated EVL and NTRK3 genes. Where the conventional technique was able to 
detect 1 methylated NTRK3 allele in a background of 125 unmethylated alleles, the new method 
detected 1 out of 3125. Moreover, low levels of EVL methylation were not detected in either of nine 
samples of normal colon mucosa from people with colorectal cancer using conventional MethyLight 
PCR, but MethyLight ddPCR selectively detected and absolutely quantified methylated EVL in all 
nine samples. 
The detection of infrequent methylation events in various clinical specimens is crucial, both for 
identifying cancer-associated epigenetic alterations that may be risk biomarkers, and for the early 
detection of colorectal cancer using blood or stool samples. "The ultimate goal for implementation of 
a sensitive detection tool like ddPCR Methylight is to determine its ability to detect methylated DNA 
in body fluid samples like blood, urine, or stool and to study normal tissue for evidence of field 
cancerization," explained Dr. Yu, who believes that ddPCR MethyLight is well suited to address 
many of the technical challenges associated with these applications, such as contaminating 
background DNA or the presence of various DNA polymerase inhibitors. 
With this study, the investigators have demonstrated proof of principle of the technique, which is 
currently being validated through further assessment of other risk biomarker candidates. Dr Yu is 
optimistic: "It will improve the sensitivity and precision for detecting infrequently methylated genes 
and will allow us to conduct studies to determine if methylated genes can be used as colon cancer 
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risk biomarkers." In the long run, these biomarkers could facilitate and improve the effectiveness of 
personalized cancer prevention programs, hopefully decreasing the mortality of colorectal cancer - 
currently the second leading cause of cancer-related death in the United States. 
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